Strongyloides stercoralis infection

@article{Greaves2013StrongyloidesSI,
  title={Strongyloides stercoralis infection},
  author={Daniel Greaves and Sian Coggle and Christopher Pollard and Sani Hussaini Aliyu and Elinor M Moore},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
#### Summary points Strongyloides stercoralis is an intestinal helminth that infects humans through contact with soil containing the larvae. Between 30 and 100 million people are infected worldwide.1 In the United Kingdom, strongyloidiasis is seen predominantly in migrants and returning travellers from endemic areas in the tropics and subtropics. Strongyloidiasis may present with cutaneous or gastrointestinal symptoms but is asymptomatic in over 60% of cases and only indicated by a raised… 

Strongyloides stercoralis

Patients with exposure to endemic areas and those expected to become immune suppressed should be screened and treated before starting immune suppressive agents, and empirical treatment should be considered when timely testing is not readily available.

Novel approaches to the diagnosis of Strongyloides stercoralis infection.

Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease

Clinicians should consider SHS in the differential diagnosis of acutely ill patients with multiple organ damage and epidemiological risk factors, especially with delayed anti-parasitic treatment.

Strongyloides stercoralis Hyper infection Syndrome

A case of hyper infection syndrome of strongyloidiasis is summarized and the various aspects of Strongyloides stercoralis infection with emphasis on life cycle of the parasite and different clinical features of the disease are discussed.

Infection and Hyperinfection with Strongyloides stercoralis: Clinical Presentation, Etiology of Disease, and Treatment Options

Improved diagnostic tests and molecular epidemiology are highlighting the underappreciated burden of disease, which could be addressed with mass chemotherapy with proven effective drugs like ivermectin.

Strongyloides stercoralis Infection in Alcoholic Patients

The early diagnosis of strongyloidiasis and treatment can prevent serious forms of hyperinfection in ethanol abusers, as shown by a fivefold higherStrongyloides stercoralis frequency in alcoholics than in nonalcoholics.

Diagnosis of Strongyloides stercoralis by morphological characteristics combine with molecular biological methods

Diagnosis with strongyloidiasis by morphological characteristics combine with molecular biological methods can improve the sensitive of diagnosis and provide a final diagnosis for the disease in the clinics.

Two Cases of Meningitis Associated with Gram Negative Bacteremiae and Strongyloidiasis

Strongyloidiasis should not be underdiagnosed, as a specific treatment with antiparasitic drugs is available, and direct microscopy of the stool should be performed in patients who develop severe enterobacterial infection when patients are from an endemic area.
...

References

SHOWING 1-10 OF 42 REFERENCES

Diagnosis of Strongyloides stercoralis infection.

  • A. SiddiquiS. Berk
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
The clinical manifestations of strongyloidiasis are described as well as various diagnostic tests and treatment strategies, and several immunodiagnostic assays have been found ineffective in detecting disseminated infections and show extensive cross-reactivity with hookworms, filariae, and schistosomes.

Clinical and epidemiological features of 33 imported Strongyloides stercoralis infections.

Strongyloidiasis in Man 75 Years after Initial Exposure

Although the patient exhibited poor general condition, he likely did not experience hyperinfection syndrome because he was not immunosuppressed, and he completely recovered after receiving standard ivermectin treatment, highlighting the importance of systematically considering chronic strongyloidiasis when seeking a diagnosis for persistent hypereosinophilia.

Strongyloidiasis in transplant patients.

  • A. RoxbyG. GottliebA. Limaye
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
Current strategies for prevention, diagnosis, and treatment of chronic intestinal strongyloidiasis in patients who will undergo transplantation are reviewed and the clinical features and management of Strongyloides hyperinfection syndrome in transplant recipients are discussed.

Imported strongyloidosis: a longitudinal analysis of 31 cases.

The results of this case series confirm that ivermectin is the drug of choice in treating imported strongyloidosis, and response to therapy can be assessed by serology and differential white blood count performed over 6 months after therapy.

Hypereosinophilic syndrome and mepolizumab.

One safety concern for mepolizumab’s use, beyond a clinical trial, is the importance of excluding occult parasitic infections, most importantly Strongyloides stercoralis. Suppression of eosinophilia

Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru.

Strongyloides hyperinfection among Peruvian patients was highly associated with HTLV-1 infection.

Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis

The use of newer diagnostic tests and broader screening of immunocompromised patients from Strongyloides-endemic areas is of paramount importance, particularly if prevention of life-threatening dissemination is the goal.

Sexual transmission of Strongyloides stercoralis among homosexual men.

Evidence implicating the sexual transmission of a helminthic parasite, Strongyloides sterocoralis, among gay men in Los Angeles County is reported.

Donor-Derived Strongyloides stercoralis Infections in Renal Transplant Recipients

This study indicates that parenteral ivermectin can be used safely and effectively in patients in whom severe malabsorption would preclude the effective use of oral formulation, and suggests that reconsideration should be given for the safety of steroids in donor-preconditioning regimens.